News

New on MS crossroads

2004

July 31, 2004 High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
May 30 Campath-1H for ms, David's experience, links.
April 30, 2004 Abstracts from the 2004 AAN meeting
September 26, 2003 Dose and Frequency of Administration of Interferon-Beta Affect its Efficacy in Multiple Sclerosis. Clin Drug Invest 23(9) 2003. Registration required, free.
September 8, 2003 New and emerging treatment options for multiple sclerosis
August 12, 2003 Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis.
August 12, 2003 Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study
July 23, 2003 Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis
June 26, 2003 natalizumab PubMed. ANTEGREN (natalizumab) by Elan.
June 18, 2003 ACTRIMS 2003
June 9, 2003 ECTRIMS 2003
June 3, 2003 Fatigue associated with multiple sclerosis: diagnosis, impact and management
April 23, 2003 Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis, Published in Nature. Collateral damage repaired by LAWRENCE STEINMAN.
April 23, 2003 Multiple sclerosis: a two-stage disease by LAWRENCE STEINMAN.
April 10, 2003 American Academy of Neurology (AAN) 55th Annual Meeting Speakers' Abstracts about Multiple Sclerosis
March 24, 2003 Betaseron (Interferon Beta-1b) Gains Expanded FDA Labeling Approval for Treating Relapsing Forms of Multiple Sclerosis
March 11, 2003 Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.
February 13, 2003 Beta-Interferon treatment does not always slow the progression of axonal injury in ms

2002

October 29, 2002 ACTRIMS and ECTRIMS -Highlights, by Cowboy.
October 25, 2002 MScare, June 2002
October 4, 2002 Novantrone research from ECTRIMS conference
September 27, 2002 ACTRIMS/ECTRIMS 2002
September 9, 2002 The "Cari Loder regime" in the treatment of multiple sclerosis
August 28, 2002 Treatment with modafinil significantly improves fatigue and sleepiness and is well tolerated by patients with MS.
August 12, 2002 EPVA Quarterly Report
July 10, 2002 Journal of Rehabilitation Research and Development, March/April 2002, Vol. 39, No 2
June 27, 2002 Multiple sclerosis, Lancet 2002; 359: 1221­31 by Prof Alastair Compston
May 8, 2002 Mitoxantrone therapy
May 6, 2002 Advances In MS Research Reported At AAN Meeting
April 12, 2002 Scientific and Medical Literature on MS Database
March 22, 2002 MS surgery experiment at Yale
March 13, 2002 Betaferon 12 years
March 13, 2002 FDA Approves Rebif (Interferon Beta-1a) For Relapsing Forms Of Multiple Sclerosis
February 23, 2002 Disease modifying therapies in multiple sclerosis: Report of the theraupeutics and technology assessment Subcommittee of the AAN and the MS Council for Clinical Practice Guidelines.
February 9, 2002 Multiple Sclerosis: Current Status and Strategies for the Future (2001)
January 30, 2002 ABC Comparison, 18 months
January 26, 2002 A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis, NEJM

• March 13, 2002 Betaferon 12 years
• March 13, 2002 FDA Approves Rebif (Interferon Beta-1a) For Relapsing Forms Of Multiple Sclerosis
• February 23, 2002 Disease modifying therapies in multiple sclerosis: Report of the theraupeutics and technology assessment Subcommittee of the AAN and the MS Council for Clinical Practice Guidelines.
• February 9, 2002 Multiple Sclerosis: Current Status and Strategies for the Future (2001)
• February 7, 2002 MScare, December 2001
• January 30, 2002 ABC Comparison, 18 months
• January 26, 2002 A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis, NEJM

2001

• December 26, 2001 Viruses and Multiple Sclerosis
• November 26, 2001 Researchers Identify Possible MS Gene, Science, Vol 294, 5547, 23 Nov 2001
• November 1, 2001 MS Guide to treatment and management
• October 26, 2001 Avonex, Copaxone combination beneficial to MS patients, study shows
• October 10, 2001 Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
• October 3, 2001 Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology. 2001 Aug 28.
• September 10, 2001 Multiple sclerosis treatment 2001
• June 29, 2001 PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
• Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b
• Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.
• Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients.
• Appraisal of Beta Interferon and Glatiramer for Multiple Sclerosis by NICE (UK).
• ECTRIMS: CHARCOT AWARD 2000-2001 to Prof. Hartmut Wekerle.
• Cooling Vest Improves Symptoms for MS Patients by AAN.
• THE MYELIN PROJECT Home Page, by the Odone family et al. Progress report 2001-8
• A Global Perspective on Multiple Sclerosis, XVII World Congress of Neurology, Day 1 - June 17, 2001
• Beta interferon for people with multiple sclerosis (MS) in UK. Sign this petition!
• A virus-induced molecular mimicry model of multiple sclerosis. - To our knowledge, this is the first study showing that a naturally infectious virus encoding a myelin epitope mimic can directly initiate organ-specific T cell-mediated autoimmunity.
• Delaying Interferon-beta-1a Treatment for MS Results in Worse Outcome
• Results of Four-Year Study of Rebif(R) Published in Neurology
• Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001 Jun 12;56(11):1496-504
• International Journal of MS Care, June 2001
• The AAN meeeting, May 2001 by NMSS.
• Stock Serono Announces Highly Significant Positive Outcome Of Rebif(R) vs Avonex(R) Study in Multiple Sclerosis
• Bladder, Bowel, and Sexual Dysfunction in Multiple Sclerosis.
• Biogen warned about misleading Avonex promotion May 2, 2001
• CALLS FOR AGGRESSIVE MS THERAPY NOT BEING HEARD IN UK
• A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations.
• European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
• MBP8298 study to Phase II
• Demyelination and axonal damage in a non-human primate model of ms. "... suggests that early axonal damage may be, at least in part, a reversible process."
• First Study to Show MS Drug Reduces MRI and Clinical Parameters in Correlated Manner
• Personality Disorder in Multiple Sclerosis Correlates With Cognitive Impairment.
• New Study with Biogen's AVONEX(R) (Interferon Beta-1a) in Secondary Progressive Multiple Sclerosis Achieves Primary Endpoint
• Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.
• Vitamin D: a natural inhibitor of multiple sclerosis.
• Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis.

2000

• ECTRIMS 2000
• Breaking news by EPVA
• FDA Approves Novantrone to Treat Progression in MS
• Researchers Identify Cognitive Fatigue in People with MS
• Cost and health related quality of life consequences of ms, Mult Scler 2000 Apr;6(2):91-8.
• Changes in Activated T Cells in the Blood Correlate With Disease Activity in Multiple Sclerosis Arch Neurol. 2000;57:1183-1189.
• Current Opinion in Neurology
• DocGuide select Neurology/multiple sclerosis channel.

1999

• MS pages by James S. Huggins. (new, good) 
• Novantrone fact sheet by Immunex 
• Axonal loss in ms by Curr Opin Neurol 1999 Jun;12(3):295-302 
• Benign ms? 
• MRI results of the PRISMS trial 
• Symptom Management: Focus On Fatigue In Multiple Sclerosis 
• The Department of Neurology at the University of Chicago Medical Center's web site devoted to MS and other neurological disease. 
• A revolutionary new wheelchair, Indetech 
• Recent important news 
• Cladribine for rr ms 
• Future computer user interface?: A device that reads brain waves through the skull has enabled paralyzed people to write sentences on a computer screen. 
• antiganglioside antibodies in pp and sp ms 
• gabapentin query 
• Mediconsult.com: Multiple Sclerosis Medical Information 
• Gabapentin - RxList Monographs 

1998

• PRISMS. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998 Nov 7;352(9139):1498-504. Full text, requires Acrobat Reader. 
• betaferon for cpms. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998 Nov 7;352(9139):1491-7. 
• ANA 1998 Meeting at Montreal by IMSSF. 
• Mitoxantrone may help spMS 
• High dose oral methylprednisolone for attacks 
• NMSS web site totally rewritten. 
• Ask MD's about MS sponsored by Berlex. 
• Incidence and significance of NAB to ifn-beta-1a 
• BMJ: Interferon beta produces only small benefits in ms 
• RESPONSES TO QUESTIONS by Dr Weinreb 
• Why Bogus Therapies Often Seem to Work by Barry L. Beyerstein, Ph.D. 
• NARCOMS by Consortium of Multiple Sclerosis Centers Committees 
• Gene therapy for EAE 
• Stress and MS 
• Mateo 2/98 
• EPVA including MS Quarterly Report 
• Multiple sclerosis - New leads into its cause and treatment by Mayo. Mayo study may explain nerve damage in MS 
• Clinical Drug Trials 
• MS Gateway by Schering. (new) 
• Beta-interferon-1b may slow secondary-progressive MS 
• NEW STUDY FINDS DAMAGE TO NERVE FIBERS IN MS by NMSS 
• Axonal Transection in the Lesions of Multiple Sclerosis ( NEJM 1998; 338: 5). Editorial: Demyelinating Diseases -- New Pathological Insights, New Therapeutic Targets 
• MS severs nerve cell fibers - study in NEJM 
• San Mateo news 1/98 
• Summary of 1997 Research Progress, by NMSS. 
• MS-Net by Serono. 
• WoMS Professional: WCN - POST-CONGRESS SYMPOSIUM 

1997

• ICAAC: HHV Implicated as Cause of MS. See also Acyclovir treatment of rr MS. 
• THE MYELIN PROJECT: Latest Report - Nov '97. 
• San Mateo news 11/97 
• Writing Accessible HTML Documents 
• Herpes viruses and ms from IMSSF. Suspicion Mounts on Herpes Virus in MS from NMSS. 
• Disappointing Results from Five Drug Trials 
• Rebif for rr ms, positive results 
• MSonly by Merle Spector and Rick Korejwo. 
• QuackWatch Home Page 
• vanha-ms32 
• MS Medical Glossary 
• flu vaccine is safe for rrMS 
• WoMS - MS Management May 1997 
• Symptom Management in 1997, by Schapiro 
• Amalgam Restorations and Multiple Sclerosis 
• IBC's International Conference on Autoimmune Diseases: Exploiting Mechanisms for Drug Development and Diagnosis 
• THE MYELIN PROJECT Home Page, Latest Report - May '97. 
• Diet and MS, Medline abstracts collected by Paivikki Parpola. 
• vanha-ms29, vanha-ms30, vanha-ms31. 
• Understanding Multiple Sclerosis by Charles S. Yanofsky, M.D. 
• New Clues to Cause of MS Progression? and Drugs Under Testing for Progressive MS by NMSS. (new) 
• The MULTIPLE SCLEROSIS Clinical Research Group 
• NMSS: Summary of 1996 research 
• THE MYELIN PROJECT Home Page, Latest Report - December '96. 
• Multiple Sclerosis Significant Others (new) 
• Laurel Highlands Multiple Sclerosis Support Group (new) 
• vanha-ms28. Cladribine, from Betaseron to Avonex, etc.